Form D · Pharmaceuticals
CATABASIS PHARMACEUTICALS INC
Boston, MA · CIK 0001454789
Offering snapshot reported Feb 8, 2021 · SEC filing
- Reported sold
- $110M Offering amount: $110M
- Investors reported
- 23 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 1, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 8, 2021 | Initial | $110,010,570 | No comparison | 23 | SEC filing |
| Feb 8, 2021 | Initial | $175,738,599 | No comparison | 6 | SEC filing |
| Mar 31, 2015 | Initial | $12,413,736 | No comparison | 20 | SEC filing |
| Nov 15, 2013 | Initial | $32,433,331 | No comparison | 11 | SEC filing |
| Jun 27, 2013 | Amendment | $9,195,865 | $445,866vs Feb 1, 2013 | 14 | SEC filing |
| Feb 1, 2013 | Initial | $8,749,999 | No comparison | 5 | SEC filing |
| Apr 14, 2010 | Initial | $7,740,526 | No comparison | 15 | SEC filing |
| Jan 15, 2010 | Amendment | $2,090,000 | $1,015,000vs May 12, 2009 | 11 | SEC filing |
| May 12, 2009 | Amendment | $1,075,000 | No comparison | Not reported | SEC filing |
| Apr 7, 2009 | Amendment | $1,000,000 | No comparison | Not reported | SEC filing |
| Jan 21, 2009 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $5.5M
- Finders' fees
- $0
- Form D file number
- 021-388817
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Jefferies LLC | 2347 |
Source: Form D, filed Feb 8, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kenneth Bate | Director |
| Joanne T. Beck | Director |
| Fred Callori | Director |
| Noah Clauser | Executive |
| Hugh Cole | Director |
| Joanne C. Donovan | Executive |
| Nicholas Galakatos | Director |
| Jean George | Director |
| Ben Harshbarger | Executive |
| Michael Jirousek | Executive |
| Michael D. Kishbauch | Director |
| Andrew Komjathy | Executive |
| Gregg Lapointe | Director |
| Ron Laufer | Director |
| Maggie Le Flore | Director |
| Jeffrey Leiden | Director |
| Jill C. Milne | Director, Executive |
| Andrew Nichols | Executive |
| Michael Ross | Director |
| Ian C. Sanderson | Executive |
| Chris Thomajan | Executive |
| Christopher Z. Thomajan | Executive |
| Jonathan Violin | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
100 High Street 28 Th Floor
Boston, MA, 02110
Boston, MA, 02110